Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS

NCT04992013 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04992013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04992013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 5, 2022
Completion date
June 1, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system cancer, metastatic cancer